Compugen SVP exercises options, sells 3,125 shares

Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold shares in a planned transaction.

Rhea-AI Filing Summary

Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold shares in a planned transaction. On April 10, 2026, she exercised options for 3,125 Ordinary Shares at exercise prices of $0.8292 and $1.15, then sold 3,125 Ordinary Shares at a weighted average price of $2.564 pursuant to a Rule 10b5-1 trading plan. Following these transactions, she directly holds 29,375 Ordinary Shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,125 shares ($5K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Levine Zurit

Role SVP, Business Development

Sold 3,125 shs ($8K)

Approx. gross sale proceeds $8K

Approx. exercise cost $3K

Approx. pre-tax spread $5K

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy)	1,125	$0.00	$0.00
Exercise	Share Option (right to buy)	2,000	$0.00	$0.00
Exercise	Ordinary Shares	1,125	$0.8292	$932.85
Exercise	Ordinary Shares	2,000	$1.15	$2K
Sale	Ordinary Shares	3,125	$2.564	$8K

Holdings After Transaction: Share Option (right to buy) — 61,625 contracts (Direct); Ordinary Shares — 29,375 shares (Direct)

Footnotes (4)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
4. F4. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Options exercised: 3,125 shares Shares sold: 3,125 shares Sale price: $2.564 per share +5 more

8 metrics

Options exercised 3,125 shares Options converted to Ordinary Shares on April 10, 2026

Shares sold 3,125 shares Ordinary Shares sold on April 10, 2026

Sale price $2.564 per share Weighted average sale price for 3,125 Ordinary Shares

Exercise price 1 $0.8292 per share Exercise price for 1,125 Share Options expiring November 9, 2032

Exercise price 2 $1.15 per share Exercise price for 2,000 Share Options expiring August 3, 2033

Post-transaction holdings 29,375 Ordinary Shares Directly held after April 10, 2026 transactions

Options position 1 after exercise 5,625 options Share Option position following 1,125-share exercise

Options position 2 after exercise 56,000 options Share Option position following 2,000-share exercise

Key Terms

Rule 10b5-1 trading plan, weighted average price, Share Option (right to buy), Ordinary Shares, +2 more

6 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Share Option (right to buy) financial

"security_title": "Share Option (right to buy)""

Ordinary Shares financial

"underlying_security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

Sale in open market or private transaction financial

"transaction_code_description": "Sale in open market or private transaction""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Compugen (CGEN) SVP Zurit Levine report?

Zurit Levine reported exercising options for 3,125 Ordinary Shares and selling 3,125 Ordinary Shares. The sale and exercises occurred on April 10, 2026 and were part of a pre-arranged Rule 10b5-1 trading plan.

How many Compugen (CGEN) shares did the SVP sell and at what price?

She sold 3,125 Ordinary Shares at a weighted average price of $2.564 per share. The shares were sold in multiple trades between $2.50 and $2.60, as disclosed in the transaction footnote.

What stock options did the Compugen (CGEN) SVP exercise in this Form 4/A?

She exercised two Share Option grants, converting rights to buy 1,125 shares at $0.8292 and 2,000 shares at $1.15 into Ordinary Shares. In total, 3,125 options were exercised into the same number of Ordinary Shares.

How many Compugen (CGEN) Ordinary Shares does Zurit Levine hold after the transactions?

After these transactions, she directly holds 29,375 Ordinary Shares. This figure reflects her position following both the option exercises and the sale reported for April 10, 2026.

Were the Compugen (CGEN) insider share sales discretionary or pre-planned?

The sales were made under a Rule 10b5-1 trading plan adopted on December 23, 2025. Such plans are pre-arranged, meaning trades execute automatically under preset conditions rather than ad hoc decisions.

What are the vesting terms of the Compugen (CGEN) options exercised by the SVP?

One option vested 25% on December 31, 2023 with the balance in 12 equal quarterly installments; another vested 25% on September 30, 2024 with the remainder in 12 quarterly installments, both subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Zurit

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Business Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/13/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/10/2026		M(1)		1,125	A	$0.8292	30,500	D
Ordinary Shares	04/10/2026		M(1)		2,000	A	$1.15	32,500	D
Ordinary Shares	04/10/2026		S(1)		3,125	D	$2.564(2)	29,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$0.8292	04/10/2026		M(1)			1,125	(3)	11/09/2032	Ordinary Shares	1,125	$0	5,625	D
Share Option (right to buy)	$1.15	04/10/2026		M(1)			2,000	(4)	08/03/2033	Ordinary Shares	2,000	$0	56,000	D

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

4. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Remarks:

This Form 4/A is being filed to correct the "Date of Earliest Transaction" reported in the original Form 4. The original Form 4, filed on April 13, 2026, mistakenly listed April 7, 2026, as the earliest transaction date, instead of the correct date of April 10, 2026. All other transaction details and holdings reported in the original filing remain unchanged.

	/s/ Zurit Levine	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)